Severe hepatotoxicity by Indian ayurvedic herbal products: A structured causality assessment

Annals of Hepatology

Volumn 8, Issue 3, 2009, Pages 258-266

  Teschke, Rolf ^a   Bahre, Ruediger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Ayurvedic herbal products; Causality assessment; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; AYURVEDIC DRUG; BAKUCHI; BILIRUBIN; BRAHMI; C REACTIVE PROTEIN; CHOLINESTERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KHADIN; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG; USHEER; PLANT EXTRACT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIBODY TITER; ARTICLE; AYURVEDA; CASE REPORT; CAUSAL ATTRIBUTION; CHOLESTASIS; COLOR ULTRASOUND FLOWMETRY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EYE JAUNDICE; FATIGUE; FEMALE; HEPATITIS A VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; IMMUNOFLUORESCENCE TEST; INDIA; LABORATORY TEST; LIVER CELL DAMAGE; LIVER TOXICITY; NAUSEA; PRURITUS; RISK BENEFIT ANALYSIS; TEA; VITILIGO; VOMITING; ACACIA; BACOPA; ECLIPTA; EPIDEMIOLOGY; HERBAL MEDICINE; MIDDLE AGED; TOXIC HEPATITIS;

ACACIA; BACOPA; CAUSALITY; DRUG-INDUCED LIVER INJURY; ECLIPTA; FEMALE; HERBAL MEDICINE; HUMANS; INDIA; MIDDLE AGED; PLANT EXTRACTS; VITILIGO;

EID: 77949366119     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31777-6     Document Type: Article

References (33)

1. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
2. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489.
3. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Brit J Clin Pharmacol 2008; 66: 758-766.
4. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S, Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. Fulminant liver failure due to us-nic acid for weight loss. Am J Gastroenterol 2004; 99: 950-952.
5. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of suspected 26 cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-93.
6. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72-84.
7. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
8. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemol 1993; 46: 1323-1330.
9. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
10. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-1104.
11. Mukerji B. Psoralea & other indigenous drugs used in leu-coderma. J Sci industry Res 1956; 15(A, Suppl.): 1-12.
12. Zimmerman HJ. Hepatotoxicity. Philadelphia: Lippincott Williams & Wilkins; 1999.
13. Moor ACE, Gasparro FP. Biochemical aspects of psoralen pho-tochemotherapy. Clin Dermatol (Phila) 1996; 14: 353-65.
14. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 1997; 25: 1407-1415.
15. von Weymarn L, Zhang QY, Ding X, Hollenberg PF. Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 2004; 26: 621-9.
16. Draper AJ, Madan A, Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Bio-chem Biophys 1997; 341: 47-61.
17. Kharasch ED, Hankins DC, Taraday JK. Single-dose me-thoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab Dispos 2000; 28: 28-33.
18. Shen D, Wu Q, Wang M, Yang Y, Lavoie EJ, Simon JE. Determination of the predominant catechins in Acacia catechubyliquid chromatography/electrospray ionization-mass spectrometry. J Agric Food Chem 2006: 54: 3219-24.
19. Singh B, Saxena AK, Chandan BK, Agarwal SG, Anand KK. In vivio hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian J Physiol Pharmacol 2001; 45: 435-41.
20. Abdel-Kader MS, Bahler BD, Malone S, Werkhoven MC, van Troon FD, Wisse JH, Bursuker I, Neddermann KM, Mamber SW, Kingston DG. DNA-damaging steroidal alkaloids from Eclipta alba from the suriname rainforest1. J Nat Prod 1998; 61: 1202-1208.
21. Chaudhuri PK, Srivastava R, Kumar S, Kumar S. Phytotoxic and antimicrobial constituents of Bacopa monnieri and Holmskioldia sanguinea. Phytother Res 2004; 18: 114-117.
22. Kim HJ, Chen F, Wang X, Chung HY, Jin Z. Evaluation of antioxidant activity of vetiver (Vetiveria zizanioides L.) oil and identification of its antioxidant constituents. J Agric Food Chem 2005; 53: 7691-5.
23. Ernst E, De Smet PAGM. Risks associated with complementary therapies (chapter 48). In: MNG Dukes (ed), Meylers's Side Effects of Drugs, Elsevier Science BV, 1996: 1427-1454.
24. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998; 339: 847.
25. Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA Jr, Cichowicz SM, Betz JM, Love LA. Contamination of botanical dietary supplements by digitalis lanata. N Engl J Med 1998; 339: 806-10.
26. Seth Ayurvedies: Brahmi Bcopa monnieri. www.sethAyurvedics.com/ayurveda-herbs/index5.html
27. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356: 1216-1225.
28. Norris PG, Hawk JLM, Baker C, Bilsland D, Diffey BL, Farr PM, Ferguson J, George SA, Gibbs NK, Green CM, Johnson BE, Marshall J, Menage H, Murphy GM, Perkins W, Proby C, Young AR. Brititsh photodermatology group guidelines for PUVA. Brit J Derm 1994; 130: 246-255.
29. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
30. Teschke, R, Schwarzenboeck A, Akinci A. Kava hepatotoxi-city: a European view. New Zeal Med J 2008; 121: 1283; ISSN 1175 8716. Available at: http://www.nzma.org.nz/journal/121-1283
31. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug- induced liver injury. Hepatology 2008; 48: 1175-1183.
32. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79: 521-528.
33. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachko-ria K, Garcia-Ruiz E, Garcia-Muhoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero- Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salme-ron J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.